About one in three people will develop shingles in their lifetime and nearly all adults aged 50 years and older carry the inactive virus that causes it. But the the risk of develo ...

Melbourne, Australia The Government has expanded access to GSK's shingles vaccine, Shingrix, to cover individuals aged 18 ...

Topline results were announced from a phase 3 study assessing the immune response following coadministration of Arexvy and Shingrix.

UK drugmaker GSK presented positive Phase III trial data at the European Geriatric Medicine Society Congress. The trial ...

Shares in vaccine developer Vaxcyte soared by over 35% Tuesday after the company unveiled results from a large study testing its experimental pneumococcal shot that analysts described as a best-case ...

GSK plc (NYSE:GSK) released topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity, ...

Co-administration of the RSV and shingles adjuvanted vaccines was well tolerated, with acceptable reactogenicity and safety ...

PHN is characterised by pain lasting from three months to several years after the rash subsides, and it is also the most ...

A man in Saudi Arabia diagnosed with shingles suffered a rare and potentially life-threatening infection that ate away the ...

A probate court in Nevada is set to begin reviewing evidence this week in a behind-closed-doors dispute that could determine ...

Public health authorities outline who needs which vaccines, organized by age and other key variables—important information ...